Date: 2011-07-27
Type of information: Development agreement
Compound: torezolid
Company: Bayer (Germany) Trius Therapeutics (USA)
Therapeutic area: Infectious diseases
Type agreement: development
commercialisation
Action mechanism:
Disease: acute bacterial skin and skin structure infections
Details: Bayer HealthCare and Trius Therapeutics have signed an exclusive agreement to develop and commercialize Trius’ lead antibiotic, torezolid phosphate (torezolid), in China, Japan and all other countries in Asia, Africa, Latin America and the Middle East, excluding North and South Korea. The companies agreed to collaborate on the development of the compound, which is already in Phase III clinical development in the US and the EU, in acute bacterial skin and skin structure infections (ABSSSI) and pneumonia caused by Gram-positive bacteria both globally and in the Bayer territory. Trius retains full development and commercialization rights for the United States, Canada and the European Union.
Financial terms: Bayer will pay Trius $ 25 million upfront and will partly bear future development costs required for global approval in ABSSSI and pneumonia. In addition, Trius is eligible to receive up to $ 69 million upon the achievement of certain development, regulatory and commercial milestones and will receive double-digit royalties on net sales of torezolid in the licensed territory.
Latest news:
